CA2199400C - Therapie photodynamique dans l'inactivation cellulaire selective dans le sang et traitement de maladies induites par une dysfonction immunitaire - Google Patents

Therapie photodynamique dans l'inactivation cellulaire selective dans le sang et traitement de maladies induites par une dysfonction immunitaire Download PDF

Info

Publication number: CA2199400C
Authority: CA; Canada
Prior art keywords: use according; fluid; porphyrin; subject; fraction
Prior art date: 1994-09-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002199400A

Other languages

English (en)

Other versions

CA2199400A1 (fr

Inventor

Simon Leong

Agnes How-Ching Chan

David William Carey Hunt

Martin Renke

Janice North

Julia Levy

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of British Columbia

Novelion Therapeutics Inc

Original Assignee

University of British Columbia

QLT Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-22

Filing date

1995-09-22

Publication date

2006-02-14

1994-09-22 Priority claimed from US08/309,509 external-priority patent/US5807881A/en

1995-09-22 Application filed by University of British Columbia, QLT Inc filed Critical University of British Columbia

1996-03-28 Publication of CA2199400A1 publication Critical patent/CA2199400A1/fr

2006-02-14 Application granted granted Critical

2006-02-14 Publication of CA2199400C publication Critical patent/CA2199400C/fr

2015-09-22 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

210000004369 blood Anatomy 0.000 title claims abstract description 40
239000008280 blood Substances 0.000 title claims abstract description 40
238000002428 photodynamic therapy Methods 0.000 title abstract description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 9
230000002779 inactivation Effects 0.000 title description 5
208000026278 immune system disease Diseases 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 107
201000006417 multiple sclerosis Diseases 0.000 claims abstract description 30
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 20
210000004027 cell Anatomy 0.000 claims description 57
150000004032 porphyrins Chemical class 0.000 claims description 41
239000012530 fluid Substances 0.000 claims description 33
210000000265 leukocyte Anatomy 0.000 claims description 33
125000000217 alkyl group Chemical group 0.000 claims description 24
-1 porphyrin compound Chemical class 0.000 claims description 20
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims description 14
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 14
125000003118 aryl group Chemical group 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 13
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims description 10
238000009826 distribution Methods 0.000 claims description 10
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
150000002148 esters Chemical group 0.000 claims description 8
150000003839 salts Chemical group 0.000 claims description 8
208000023275 Autoimmune disease Diseases 0.000 claims description 7
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 7
150000001408 amides Chemical group 0.000 claims description 7
238000001212 derivatisation Methods 0.000 claims description 6
229920002554 vinyl polymer Polymers 0.000 claims description 6
125000004181 carboxyalkyl group Chemical group 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
230000002829 reductive effect Effects 0.000 claims description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical group N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 claims description 3
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 3
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
125000000962 organic group Chemical group 0.000 claims description 3
229960004293 porfimer sodium Drugs 0.000 claims description 3
BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
230000001766 physiological effect Effects 0.000 claims description 2
125000001475 halogen functional group Chemical group 0.000 claims 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
208000030963 borderline personality disease Diseases 0.000 description 54
206010006475 bronchopulmonary dysplasia Diseases 0.000 description 54
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 45
239000000906 photoactive agent Substances 0.000 description 44
238000000034 method Methods 0.000 description 28
239000000203 mixture Substances 0.000 description 23
125000001424 substituent group Chemical group 0.000 description 23
239000007924 injection Substances 0.000 description 20
238000002347 injection Methods 0.000 description 20
230000000694 effects Effects 0.000 description 16
210000001519 tissue Anatomy 0.000 description 14
241000725303 Human immunodeficiency virus Species 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
238000007792 addition Methods 0.000 description 10
210000001124 body fluid Anatomy 0.000 description 10
239000010839 body fluid Substances 0.000 description 10
125000005843 halogen group Chemical group 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 9
238000009472 formulation Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 8
238000005698 Diels-Alder reaction Methods 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 7
210000001185 bone marrow Anatomy 0.000 description 6
230000007423 decrease Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
201000002491 encephalomyelitis Diseases 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
230000005855 radiation Effects 0.000 description 6
238000000862 absorption spectrum Methods 0.000 description 5
230000001678 irradiating effect Effects 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 4
125000004122 cyclic group Chemical group 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
238000007910 systemic administration Methods 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
208000009386 Experimental Arthritis Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
208000010642 Porphyrias Diseases 0.000 description 3
241000700605 Viruses Species 0.000 description 3
125000002947 alkylene group Chemical group 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
125000001246 bromo group Chemical group Br* 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000000539 dimer Substances 0.000 description 3
230000003292 diminished effect Effects 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 2
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000047918 Myelin Basic Human genes 0.000 description 2
101710107068 Myelin basic protein Proteins 0.000 description 2
150000000475 acetylene derivatives Chemical class 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 2
150000004035 chlorins Chemical class 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000000779 depleting effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
229960003569 hematoporphyrin Drugs 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
125000002346 iodo group Chemical group I* 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
150000004033 porphyrin derivatives Chemical class 0.000 description 2
230000008569 process Effects 0.000 description 2
229950003776 protoporphyrin Drugs 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
125000005916 2-methylpentyl group Chemical group 0.000 description 1
MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000000503 Collagen Type II Human genes 0.000 description 1
108010041390 Collagen Type II Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000007259 addition reaction Methods 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000005670 electromagnetic radiation Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
230000005283 ground state Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
AHAREKHAZNPPMI-UHFFFAOYSA-N hexadiene group Chemical group C=CC=CCC AHAREKHAZNPPMI-UHFFFAOYSA-N 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
238000005286 illumination Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
LCPSIJJDZWNVRJ-UHFFFAOYSA-L in-protoporphyrin ix Chemical compound C1=C(N2[In]N34)C(C=C)=C(C)C2=CC(=N2)C(C)=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4C=C2C(C=C)=C(C)C1=N2 LCPSIJJDZWNVRJ-UHFFFAOYSA-L 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000003007 myelin sheath Anatomy 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000002186 photoactivation Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
150000003233 pyrroles Chemical class 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002199400A 1994-09-22 1995-09-22 Therapie photodynamique dans l'inactivation cellulaire selective dans le sang et traitement de maladies induites par une dysfonction immunitaire Expired - Fee Related CA2199400C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/309,509 US5807881A (en)	1992-05-27	1994-09-22	Method for selectively reducing activated leukocyte cell population
US08/309,509		1994-09-22
PCT/CA1995/000543 WO1996009068A1 (fr)	1994-09-22	1995-09-22	Therapie photodynamique dans l'inactivation cellulaire selective dans le sang et traitement de maladies induites par une dysfonction immunitaire

Publications (2)

Publication Number	Publication Date
CA2199400A1 CA2199400A1 (fr)	1996-03-28
CA2199400C true CA2199400C (fr)	2006-02-14

Family

ID=35892305

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002199400A Expired - Fee Related CA2199400C (fr)	1994-09-22	1995-09-22	Therapie photodynamique dans l'inactivation cellulaire selective dans le sang et traitement de maladies induites par une dysfonction immunitaire

Country Status (1)

Country	Link
CA (1)	CA2199400C (fr)

1995
- 1995-09-22 CA CA002199400A patent/CA2199400C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2199400A1 (fr)	1996-03-28

Legal Events

Date	Code	Title	Description
1998-12-30	EEER	Examination request
2010-09-22	MKLA	Lapsed

Publication	Publication Date	Title
AU708142B2 (en)	1999-07-29	Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
EP0642342B1 (fr)	2000-07-12	Inactivation selective de cellules dans le sang
KR100256853B1 (ko)	2000-05-15	혈관 내막과 형성 증진을 억제하기위한 약제학적 조성물
US5368841A (en)	1994-11-29	Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides
EP0468997A1 (fr)	1992-02-05	Derives de bacteriochlorophylle-a utiles a la therapie photo-dynamique.
US5789433A (en)	1998-08-04	Green porphyrins as immunomodulators
Guardiano et al.	1989	Tetra-n-propylporphycene as a tumour localizer: pharmacokinetic and phototherapeutic studies in mice
CA2199400C (fr)	2006-02-14	Therapie photodynamique dans l'inactivation cellulaire selective dans le sang et traitement de maladies induites par une dysfonction immunitaire
Cuomo et al.	1991	Tumour-localising and-photosensitizing properties of liposome-delivered Ge (IV)-octabutoxy-phthalocyanine
US6096776A (en)	2000-08-01	Green porphyrins as immunomodulators